Ciara Metcalfe
Overview
Explore the profile of Ciara Metcalfe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1200
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liang J, Yao X, Aouad P, Wang B, Crocker L, Chaudhuri S, et al.
Nat Cancer
. 2025 Jan;
6(2):357-371.
PMID: 39805955
Multiple next-generation molecules targeting estrogen receptor α (ERα) are being investigated in breast cancer clinical trials, encompassing thousands of women globally. Development of these molecules was partly motivated by the...
2.
Maulding N, Zou J, Zhou W, Metcalfe C, Stuart J, Ye X, et al.
NPJ Syst Biol Appl
. 2025 Jan;
11(1):5.
PMID: 39794360
Understanding transcriptional heterogeneity in cancer cells and its implication for treatment response is critical to identify how resistance occurs and may be targeted. Such heterogeneity can be captured by in...
3.
Kuemmel S, Harper-Wynne C, Park Y, Franke F, De Laurentiis M, Schumacher-Wulf E, et al.
BMC Cancer
. 2024 May;
24(1):641.
PMID: 38789924
Background: HER2-positive, estrogen receptor-positive breast cancer (HER2+, ER+ BC) is a distinct disease subtype associated with inferior response to chemotherapy plus HER2-targeted therapy compared with HER2+, ER-negative BC. Bi-directional crosstalk...
4.
Chaudhary N, Chibly A, Collier A, Martinalbo J, Perez-Moreno P, Moore H, et al.
NPJ Breast Cancer
. 2024 Feb;
10(1):15.
PMID: 38388477
As CDK4/6 inhibitor (CDK4/6i) approval changed treatment strategies for patients with hormone receptor-positive HER2-negative (HR+/HER2-) breast cancer (BC), understanding how exposure to CDK4/6i affects the tumor genomic landscape is critical...
5.
Will M, Liang J, Metcalfe C, Chandarlapaty S
Nat Rev Cancer
. 2023 Jul;
23(10):673-685.
PMID: 37500767
The hormone receptor oestrogen receptor-α (ER) orchestrates physiological mammary gland development, breast carcinogenesis and the progression of breast tumours into lethal, treatment-refractory systemic disease. Selective antagonism of ER signalling has...
6.
Chandarlapaty S, Dickler M, Perez Fidalgo J, Villanueva-Vazquez R, Giltnane J, Gates M, et al.
Clin Cancer Res
. 2023 Jun;
29(15):2781-2790.
PMID: 37261814
Purpose: GDC-0927 is a novel, potent, nonsteroidal, orally bioavailable, selective estrogen receptor (ER) degrader that induces tumor regression in ER+ breast cancer xenograft models. Patients And Methods: This phase I...
7.
Liang J, Ingalla E, Yao X, Wang B, Tai L, Giltnane J, et al.
Sci Transl Med
. 2022 Sep;
14(663):eabo5959.
PMID: 36130016
(estrogen receptor 1) hotspot mutations are major contributors to therapeutic resistance in estrogen receptor-positive (ER) breast cancer. Such mutations confer estrogen independence to ERα, providing a selective advantage in the...
8.
Metcalfe C, Lauchle J
Adv Exp Med Biol
. 2022 Sep;
1390:297-309.
PMID: 36107326
Estrogen Receptor alpha (ERα) stands as one of the most successfully prosecuted drug targets in oncology, beginning with the approval of tamoxifen for women with ERα positive (ER+) breast cancer...
9.
Kurtova A, Heinlein M, Haas S, Velten L, Dijkgraaf G, Storm E, et al.
Blood Adv
. 2022 Aug;
7(4):491-507.
PMID: 35914228
Self-renewal and differentiation of stem and progenitor cells are tightly regulated to ensure tissue homeostasis. This regulation is enabled both remotely by systemic circulating cues, such as cytokines and hormones,...
10.
Munne P, Martikainen L, Raty I, Bertula K, Nonappa , Ruuska J, et al.
Nat Commun
. 2021 Nov;
12(1):6967.
PMID: 34845227
Breast cancer is now globally the most frequent cancer and leading cause of women's death. Two thirds of breast cancers express the luminal estrogen receptor-positive (ERα + ) phenotype that...